Clear Search

Showing 2 results for “Li M”.

November 2025

Efficacy and safety of allogeneic CD19 CAR NK-cell therapy in systemic lupus erythematosus: A case series in China

Lancet 2025 Doi:10.1016/S0140-6736(25)01671-X Epub ahead of print

Gao et al. report that allogeneic CAR NK-cell therapy is a potent option for treatment of autoimmune diseases and may address limitations of current autologous CAR T-cell therapy, including manufacturing scale and time, access, safety, and cost. Authors evaluated the safety, tolerability, and efficacy of allogeneic CD19 CAR NK-cell therapy in patients with relapsed or refractory SLE.

more…

January 2025

The 2024 APLAR consensus on the management of lupus nephritis

International Journal of Rheumatic Diseases; 28:e70021 DOI: 10.1111/1756-185X.70021

Mok et al. provided updated consensus recommendations from APLAR, emphasising evidence-based guidance for managing lupus nephritis in Asian populations. These recommendations consider ethnic, socioeconomic, and pharmacogenetic factors, focusing on treatment regimens, adjunctive therapies, and patient-specific approaches to optimise outcomes.

more…